Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nagoya
Clinical trial register · Japan

Clinical Trials in Nagoya, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Sapporo 33 Nagoya 30 Yokohama 27 Fukuoka 19 Suita 19
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC53 AbbVie46 AstraZeneca36 Pfizer31 Novartis Pharmaceuticals30 Clear sponsor filter
Site location
Sapporo33 Nagoya30 Yokohama27 Fukuoka19 Suita19
All 135 locations
Target enrolment
to

Trials with a site in Nagoya

30 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
DrugAtrasentan
Novartis Pharmaceuticals
Phase 3
28
Nagoya, Kanazawa, Chiba, Fukuoka
2026-08-06
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Nagoya, Gifu, Bunkyo Ku, Kodaira, Yonago
2026-06-03
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Nagoya, Seto, Hirosaki, Asahi, Funabashi, Matsudo, Kitakyushu, Ōgaki
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Nagoya, Urayasu, Shinjuku Ku, Kofu, Niigata
2026-03-09
Active, closed
Novartis Pharmaceuticals
Phase 1
6
Nagoya, Kobe, Bunkyo Ku, Koto Ku
2025-11-26
Active, closed
Fabhalta Capsules Specified Drug-use Survey
NCT07156149C3 Glomerulopathy
Novartis Pharmaceuticals
Observational
33
Nagoya, Toyoake, Hirosaki, Chiba, Fukuoka, Kitakyushu, Sapporo, Tsukuba
2025-09-17
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Nagoya, Sapporo, Kobe, Kamakura, Yokohama, Kumamoto, Chuo Ku, Chiba
2025-07-01
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Nagoya, Matsudo, Kawasaki, Yokohama, Habikino, Shinagawa Ku, Fukuoka, Kyoto
2025-05-16
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Nagoya, Toyoake, Yokohama, Iruma-gun, Bunkyo-ku, Shinjuku Ku, Toyama, Hiroshima
2024-10-09
Active, closed
Specified Drug-use Surveillance of Fabhalta Capsules
NCT06606314Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Observational
132
Handa, Nagoya, Okazaki, Toyohashi, Toyota, Hachinohe, Chiba, Funabashi
2024-09-18
Recruiting
Revolade Tablets Specified Drug-use Survey
NCT06287268Aplastic Anemia
Novartis Pharmaceuticals
Observational
10
Nagoya, Toyoake, Chiba, Amagasaki, Kobe, Matsumoto, Shimajiri-Gun, Izumi
2024-07-17
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo-ku, Chuo Ku, Fuchū, Itabashi-ku
2024-05-21
Active, closed
Specified Drug-use Survey of Leqvio for s.c. Injection.
NCT06275724Familial Hypercholesterolaemia, Hypercholesterolaemia
Novartis Pharmaceuticals
Observational
585
Handa, Ichinomiya, Komaki, Nagoya, Toyoake, Tsushima, Asahi, Inzai
2024-03-04
Recruiting
Special Drug Use-results Surveillance of Tafinlar/Mekinist
NCT06262919BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
DrugDabrafenib/trametinib
Novartis Pharmaceuticals
Observational
110
Nagakute, Nagoya, Toyohashi, Toyota, Daisen, Chiba, Funabashi, Kashiwa
2024-02-09
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Nagoya, Kitakyushu, Sapporo, Yokohama, Kuwana, Sasebo, Kurashiki, Bunkyo Ku
2023-10-27
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo Ku, Bunkyo-ku, Chuo Ku, Fuchū
2023-03-02
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Nagoya, Osaka, Suita, Kofu, Kumamoto
2023-02-02
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Nagoya, Urayasu, Obihiro, Yokohama, Kamimashi-gun, Izumiōtsu, Neyagawa, Sakai
2022-12-09
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Nagoya, Kitakyushu, Sapporo, Yokohama, Kuwana, Sasebo, Kurashiki, Bunkyo Ku
2022-08-04
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Nagoya, Chiba, Ichihara, Fukuoka, Sapporo, Kobe, Nishinomiya, Isehara
2021-12-13
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Nagoya, Toyoake, Sapporo, Kobe, Kurashiki, Sakai, Suita, Shimotsuke
2021-10-06
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Nagoya, Asahikawa, Sapporo, Takatsuki, Ohtsu, Niigata
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Nagoya, Isehara, Suwa, Suita, Shinjuku Ku, Fukushima, Ishikawa, Kyoto
2021-07-27
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Nagoya, Sapporo, Kobe, Yokohama, Kumamoto, Suita, Kitaadachi-gun, Bunkyo Ku
2021-06-09
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Nagoya, Kashiwa, Osaka, Chuo Ku, Koto Ku
2021-02-24
Active, closed
Novartis Pharmaceuticals
Phase 2
24
Nagoya, Kashiwa, Isehara, Yokohama, Kumamoto, Sendai, Osaka, Suita
2021-01-08
Recruiting
Study of Out of Specification for Tisagenlecleucel
NCT04094311B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
DrugTisagenlecleucel
Novartis Pharmaceuticals
Phase 3
200
Nagoya, Tōon, Gifu, Sapporo, Kobe, Nishinomiya, Tsukuba, Kita-gun
2019-11-21
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Nagoya, Asahikawa, Sapporo, Takatsuki, Ohtsu, Hachiōji, Niigata
2019-10-03
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Nagoya, Fukuoka, Akashi, Koto Ku
2015-12-11
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Nagoya, Sapporo, Isehara, Suita, Bunkyo Ku, Fukuoka, Osaka
2015-03-05
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/nagoya

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Nagoya that also match the filters currently applied.

How many clinical trials are recruiting in Nagoya?

11 of the 30 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nagoya), 30 studies
PhaseStudiesRecruitingShare
Phase 317756.7%
Observational5216.7%
Phase 24213.3%
Phase 4206.7%
Phase 1103.3%
Phase 1/2103.3%

Most active sponsors

Lead sponsors with the most studies (Nagoya)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals3011
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.